{"name":"Cara Therapeutics, Inc.","slug":"cara-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":5533000,"revenueGrowth":9.3,"grossMargin":0,"rdSpend":32805000,"netIncome":-70867000,"cash":43827000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2018"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"CR845","genericName":"CR845","slug":"cr845","indication":"Moderate-to-severe pruritus in patients with chronic kidney disease on hemodialysis","status":"phase_3"}]}],"pipeline":[{"name":"CR845","genericName":"CR845","slug":"cr845","phase":"phase_3","mechanism":"CR845 is a selective kinin B1 receptor antagonist that blocks inflammatory signaling to reduce pruritus and other inflammatory symptoms.","indications":["Moderate-to-severe pruritus in patients with chronic kidney disease on hemodialysis","Pruritus associated with atopic dermatitis (exploratory)"],"catalyst":""}],"recentEvents":[],"realNews":[{"date":"2026-03-31","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-31","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-03-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-01-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-12-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-11-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxONXpoQVk2NkFxdDdQb3VraDBmaklIZVpmVUVrbnVyTTA5MnVJMFhIZzM0VzR6WmlVMTlCMy1yd2JjQ2FNOXd1YzRycDZ1R21xYl9sbllEZ1pUd3FfV1FzTzJqb1FwX2JFSlU5SklnUGJWZGE3MGFXUDVGZGI4MUo5dlM2UGpfUFRRd3B4Tl93SUQybTBTNG84YW9uUndLQWw5d2xQazI3RW81eVBoeW53U2tsdndZWmV2aFJwbmdhUGczRFE?oc=5","date":"2025-02-06","type":"pipeline","source":"Investing.com","summary":"Cara Therapeutics CEO Christopher Posner sells $1,755 in stock - Investing.com","headline":"Cara Therapeutics CEO Christopher Posner sells $1,755 in stock","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxNeDhTU1JhMFN5WEoybGxEY2UyYzd0NWF5eHp0ZVJXUVFEWU9jLWtyVDFTU2tCbHQ3VkRuY2Y3S1dTVDZSdG9BQUtRaHJFWHNuZEZMNmt3NmhtaXhrQ0hPeTZOeEhRYThRcDhYR202X24waEZwLURhNHl2UXJMcklleHZ1Y2lIaG1mbXl1RjV4am5Jd1V0MS0tYzRrc2o2LXRvdG1UTA?oc=5","date":"2024-12-18","type":"pipeline","source":"Hartford Business Journal","summary":"Stamford’s Cara Therapeutics to merge with Houston biopharma firm - Hartford Business Journal","headline":"Stamford’s Cara Therapeutics to merge with Houston biopharma firm","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxOVGU4MkNUZ3lObFR1SHM0bVdfLW12Z0hpQnFSOGVaUkk4aXJxcUtMZlkycjBhRGJxbTFBbXlMN1NyYmtub0lwWWpIUl9ueGc3Y19BV1JlWnhrV1NjVXdvWU9yMDZGSTkzbXZVRV9SR0pyTVUyTnU0cmx6V0ozZnp4WUJtS3RMRmVvZWRKSDlscnVQNzhyTEFCOWpsWEZGX2JRdE9neWtYTDk4dHcxVWJ4dWNDWlBOU3poZ1MySGRQLXVZYnEyLWZ0c2c3WEgyaEJSYUdCSExpQVBybHRLSDJYQnRVZGk?oc=5","date":"2024-12-18","type":"deal","source":"GlobeNewswire","summary":"Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement - GlobeNewswire","headline":"Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPZ1ozd2RKaE02ZEtqTUhtUVBQeVhldE5XYVRlQVc1XzRZaUlpRVhCMFZPRi1sTHdXM0phNW5zcmRiTjRDRm1ZNU51YzN0QXFYR09GQnM5WE9uWkdNVFF4dEU3aXQxS0N3aENXbmwweVRVZTdTbS1JZlI2b0FWS1cyLTRac1RMSEZ5Mzg1LWlOZk1waVU?oc=5","date":"2024-12-18","type":"pipeline","source":"citybiz","summary":"Cara Therapeutics and Tvardi Therapeutics To Merge - citybiz","headline":"Cara Therapeutics and Tvardi Therapeutics To Merge","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMicEFVX3lxTE9ROFBPdENZOTVqZmFjcEdlYXJrejhzQkZLQ1dKSFo3bVBBQnlkR2MtbjZSbk5zX295eHFzSXRLTFdrc29qd1M1RHRTY0xfdjNRdlpiOTBGYlU0WUtNdmRNdFRUQ203VTBTU2lWT1FOQmw?oc=5","date":"2024-06-30","type":"pipeline","source":"The Pharma Letter","summary":"Cara Therapeutics - The Pharma Letter","headline":"Cara Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAJBVV95cUxPMzMzTEo4Tjg1MXZsVTBqcUpmUVpSS0NLY01LWHFSdjQ4VDNPdkR4OEdOZC0xOWNwZ2dsTzZRUWYyTlNEc3FQRk52d1Zpb0ZSc1VIcGkwNDJrX3BMMk5NZW1fV1lPZy1HLW9VWWxmWHJrRXpES3BFbXVlOWRTeHI2V0RtcUF6TG4wWm1rb0trbVI0SVRlelZBYW1EdjdwYmt2LUpwRU84dC1kVEtjVjMtY0xiV0IwZzRldXBiTHJMdWtKeW1DZGs2WVFFLXp5U2JKVzlYRHJqNW9NM043bldITXd6NFFDZmJ2NVRJbE9HaFd4Y2RvNzJ2ejg4VlhCSzFqSWRKRUZ0R1FMVHh1bHBkbQ?oc=5","date":"2023-05-18","type":"pipeline","source":"PR Newswire","summary":"Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus - PR Newswire","headline":"Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associat","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOUkxSZmdSVEUtY3BMMHpvNDVNbWI3cUx3ZUdsNm94VU9iSkI0X0FleTlGVTZ5WVpjdEF5WWhwelZxVVk4VjloUjN3amM5WGNkVEJBcWVwZ1htVkVHZjhpZkpjYWFhVzBpeHpyUVlLaWNGR2lrczNtNE1OZGxlOGZzZkZuZkpFdGV0b1c5MW1kMndRSjgyeTFxTFp4dw?oc=5","date":"2022-09-28","type":"pipeline","source":"Yahoo Finance","summary":"Cara Therapeutics Announces Difelikefalin (KORSUVA®) Injection New Drug Application Has Been Submitted in Japan - Yahoo Finance","headline":"Cara Therapeutics Announces Difelikefalin (KORSUVA®) Injection New Drug Application Has Been Submitted in Japan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxNWjJTMmNWZVQwVDhmT0hta1hiX3FKUGMwLVBQZ3B1UlRObGwycVpqS0hHeDhoLUpmRTJwSUItSENoRVF2RDZOUE1aQmVLZ1ZPNXFXamlmZ3FCMmVHMU9xMGNJQXlfd2hwaTVRM2ZjRTRIVy1IWkN5YzFrX2hralk4RXphaHYtcGRTRXc?oc=5","date":"2022-02-23","type":"pipeline","source":"Pharmacy Times","summary":"Korsuva From Cara Therapeutics and Vifor Pharma - Pharmacy Times","headline":"Korsuva From Cara Therapeutics and Vifor Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxONC1LeUJaa0N0TkU0VV9ncUxDT2ZxZVdkVVdDcV8yR1BMU3VxRXdvcmdVV3ZuWWd3OHYwQ2NIZDRVNDRJalZLLV9aOUlTNzNKZkdBdmViQl9UMFhtUmtyWS1kTXVDTXF5TU90QklSNk1YaWtDem1QOEFIaXFHUHVoeDBtSDJYa2k4cVlsVWlENDBzcHY5S1daMmpLX1pTeUlwV21OQzZqell6U00?oc=5","date":"2021-11-04","type":"pipeline","source":"Stamford Advocate","summary":"Stamford-based Cara Therapeutics’ CEO to step down - Stamford Advocate","headline":"Stamford-based Cara Therapeutics’ CEO to step down","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":5533000,"revenuePeriod":"2018-12-31","revenueHistory":[{"value":5533000,"period":"2018-12-31"},{"value":5062000,"period":"2018-09-30"},{"value":2874000,"period":"2018-06-30"},{"value":911000,"period":"2017-12-31"},{"value":911000,"period":"2017-03-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":32805000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-70867000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":43827000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}